Disease Landscape and Forecast Insights

A growing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of…

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…

Clarivate Epidemiology’s coverage of human papillomavirus (HPV) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of respiratory syncytial virus (RSV) infection comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including…

Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…

The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics or targeted…

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. While…

Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…

Despite considerable progress in the treatment of HR-positive/HER2-negative metastatic breast cancer, the disease remains incurable. The approval and availability of the CDK4/6 inhibitors (Pfizer…